At this cost, there's no real need to day trade; it's easy to sell too early and miss out. The recent event-driven catalyst is that OpenAI might seek cooperation or investment with AI-driven drug discovery companies. RXRX is highly aligned, and the probability of getting an allocation is very high. If allocated, we'll aim for $5 again. In the long term, it still depends on the actual drug development progress.